BACKGROUND: The risk of @entity14 ( @entity14 ) disappearing on cross-sectional imaging has increased with advances in preoperative chemotherapy, but <50  % of disappearing @entity14 demonstrate complete pathological response. OBJECTIVE: The aim of this study was to evaluate the role of fiducial marker placement before potentially curative treatment of @entity14 at risk of disappearing with chemotherapy. METHODS: All consecutive @entity1 who underwent fiducial placement for tracking of @entity14 at a tertiary center were reviewed. RESULTS: Among 1377 @entity1 undergoing @entity14 resection between 2005 and 2015, 35 @entity1 underwent fiducial placement. Three @entity1 were excluded due to disease progression. The study population comprised 32 @entity1 who underwent fiducial placement in 41 @entity14 . Among the 41 marked @entity14 , 34 (83  %) were located >10  mm @entity409 , 25 (61  %) were in the right liver, and median size was 12  mm (range, 6-20  mm). No complication occurred after fiducial placement. After chemotherapy, 19 (46  %) of the 41 marked @entity3 disappeared on cross-sectional imaging. All fiducial-tracked @entity14 were treated with resection (n   =   31) or ablation (n   =   10). After median follow-up of 14  months (range, 0-64  months), no local recurrences were observed. CONCLUSION: Fiducial placement represents a safe procedure that facilitates accurate localization for resection or ablation of small @entity14 at risk of disappearing with chemotherapy.

Eradication of Missing XXXX After Fiducial Placement.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity409 :: ('MESH:D008107', 'Disease') :: ['deep in the liver parenchyma'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal liver metastases', 'CLM']
@entity409 :: (MESH:D008107,Disease) :: ['Liver Metastases']
